Incorrect password
evipedia.ai Suggest Edit

Naringenin for Health & Longevity

Evidence Review created on 04/25/2026 using AI4L / Opus 4.7

Also known as: 4’,5,7-Trihydroxyflavanone, (S)-Naringenin, Naringetol, Salipurol, NGEN

Motivation

Naringenin is a plant compound most abundant in grapefruit, oranges, and tomatoes. In whole foods it is most often present as the glycoside naringin, which is broken down in the gut to release the active form. It is studied primarily for its effects on lipid metabolism, glucose regulation, and inflammatory signaling.

Interest in naringenin grew from observations that grapefruit consumption alters the metabolism of many medications and from preclinical work suggesting it reduces hepatic fat and modulates cholesterol synthesis. Animal models have shown striking metabolic effects, while human evidence remains far more limited.

This review examines the evidence for and against naringenin as an intervention for health and longevity. It spans the molecular mechanisms, the dietary and supplemental forms, the small body of human trial data on cardiometabolic outcomes, the safety and drug-interaction profile rooted in citrus pharmacology, sourcing considerations, and the research directions most likely to refine the evidence base.

Benefits - Risks - Protocol - Conclusion

A curated set of high-level overviews and expert commentary providing context on naringenin, its mechanism, and its role in cardiometabolic and inflammatory pathways.

  • The Therapeutic Potential of Naringenin: A Review of Clinical Trials - Salehi et al., 2019

    A narrative review of naringenin’s pharmacological profile, biological activities, and the human trial data examining its bioavailability and cardioprotective actions, noting promising endothelial and cardiometabolic effects alongside the need for further pharmacokinetic and pharmacodynamic study.

  • Antidiabetic Properties of Naringenin: A Citrus Fruit Polyphenol - Den Hartogh & Tsiani, 2019

    A narrative review focused on naringenin’s effects on glucose homeostasis, insulin sensitivity, and beta-cell function, summarizing in vitro and animal evidence in adipose, liver, pancreas, and skeletal muscle, and noting the wide gap between preclinical promise and small-scale human data.

  • Grapefruit Juice and Some Drugs Don’t Mix - U.S. Food and Drug Administration

    An FDA consumer-update summarizing the well-characterized drug interactions caused by grapefruit constituents (including naringenin and its glycoside naringin), explaining how furanocoumarins and flavanones inhibit intestinal CYP3A4 (cytochrome P450 3A4, a major liver and gut enzyme that metabolizes more than half of all prescription drugs) with consequences for many prescription drugs.

  • Naringenin, a Flavanone with Antiviral and Anti-Inflammatory Effects - Tutunchi et al., 2020

    A narrative review of naringenin’s antiviral and anti-inflammatory mechanisms with a focus on coronavirus disease, including potential inhibition of the viral 3CLpro (3-chymotrypsin-like protease, the principal coronavirus enzyme that processes viral polyproteins) and modulation of angiotensin-converting enzyme signaling, alongside the broader anti-inflammatory profile.

  • Naringenin, a Citrus Fruit Flavonoid, Preserves Muscle Mass in Aging While Enhancing Exercise Capacity and Aerobic Metabolism Efficiency (Animal Study) - Rhonda Patrick

    A FoundMyFitness Science Digest commentary summarizing animal evidence that dietary naringenin preserves muscle mass and enhances exercise endurance and grip strength in aging mice, with proposed mechanisms involving expansion of oxidative myofibers and Sp1 (specificity protein 1, a transcription factor that regulates expression of many cell-cycle, growth, and metabolism genes) signaling, framed in the context of age-related sarcopenia.

No directly relevant long-form content focused specifically on naringenin was identified from Peter Attia (peterattiamd.com), Andrew Huberman (hubermanlab.com), Chris Kresser (chriskresser.com), or Life Extension Magazine (lifeextension.com). These platforms have addressed citrus consumption, polyphenols, and grapefruit drug interactions in broader contexts but do not appear to host dedicated naringenin-centered episodes or articles.

Grokipedia

Naringenin

Grokipedia’s entry provides a structured reference overview of naringenin as a flavanone with the molecular formula C15H12O5, covering its presence in grapefruit and other citrus fruits, its action on cytochrome P450 enzymes and lipid metabolism, and its preclinical investigation across cardiovascular, metabolic, and antiviral contexts.

Examine

No dedicated examine.com article was identified for naringenin as of 2026-04-25. Examine.com indexes citrus flavonoids primarily under whole-food entries (e.g., grapefruit) and discusses naringenin contextually within those entries rather than as a standalone supplement monograph.

ConsumerLab

No dedicated ConsumerLab article was identified for naringenin as of 2026-04-25. ConsumerLab’s product-testing focus is on more widely sold supplement categories; naringenin standalone supplements are sold but have not yet been the subject of a dedicated ConsumerLab review.

Systematic Reviews

A small but growing set of systematic reviews has examined naringenin’s pharmacological and clinical effects, focused on cardiometabolic, inflammatory, hepatic, and antiviral outcomes; the human clinical trial base remains small.

Mechanism of Action

Naringenin acts through several converging pathways, most anchored in modulation of nuclear receptors, lipid-metabolism enzymes, and inflammatory signaling:

  • PPAR activation: Naringenin activates peroxisome proliferator-activated receptors alpha and gamma (PPARα and PPARγ, nuclear receptors that regulate genes involved in fatty-acid oxidation and adipocyte differentiation). PPARα activation in the liver upregulates fatty-acid oxidation and reduces VLDL (very-low-density lipoprotein, the lipoprotein that carries triglycerides from the liver) production; PPARγ activation in adipose and muscle tissue improves insulin sensitivity. This dual nuclear-receptor profile resembles, mechanistically, the actions of fibrate (a class of lipid-lowering drugs that activate PPARα to reduce triglycerides) and thiazolidinedione (a class of insulin-sensitizing drugs that activate PPARγ) drug classes.
  • HMG-CoA reductase modulation: Naringenin reduces activity of HMG-CoA reductase (3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme in cholesterol synthesis), the same enzyme inhibited by statin drugs. This contributes to the lipid-lowering signal observed in animal and small human studies.
  • ApoB and microsomal triglyceride transfer protein: Naringenin reduces apolipoprotein B (apoB, the principal protein on LDL and VLDL particles) secretion from hepatocytes (liver cells) and modulates microsomal triglyceride transfer protein (MTP, an enzyme that loads lipids onto apoB-containing lipoprotein particles), reducing assembly and secretion of atherogenic lipoproteins.
  • CYP3A4 inhibition: Naringenin inhibits intestinal CYP3A4. This is the central mechanism behind grapefruit’s well-known drug-interaction profile, although the furanocoumarins in grapefruit (notably bergamottin and 6’,7’-dihydroxybergamottin) cause more durable irreversible CYP3A4 inhibition than naringenin alone. Naringenin also inhibits OATP1A2 and OATP2B1 (organic anion transporting polypeptides, which mediate intestinal absorption of certain drugs).
  • AMPK activation: Naringenin activates AMP-activated protein kinase (AMPK, a cellular energy sensor that switches on fat burning and switches off fat synthesis when cellular energy is low) in liver and skeletal muscle, paralleling the mechanism of metformin and contributing to improvements in glucose uptake and lipid oxidation.
  • NF-κB and MAPK suppression: Naringenin attenuates activation of nuclear factor kappa B (NF-κB, a transcription factor that drives expression of pro-inflammatory genes) and the mitogen-activated protein kinase (MAPK, a family of signaling enzymes involved in inflammation and cell proliferation) cascade, reducing pro-inflammatory cytokines (TNF-α (tumor necrosis factor alpha, a pro-inflammatory cytokine), IL-6 (interleukin-6, a pro-inflammatory cytokine)) in cell and animal studies.
  • Antioxidant activity: Naringenin scavenges reactive oxygen species directly and upregulates Nrf2 (nuclear factor erythroid 2-related factor 2, a master transcription factor that activates antioxidant defense genes), increasing expression of glutathione S-transferase, superoxide dismutase, and catalase.
  • Estrogen receptor modulation: Naringenin shows weak binding to estrogen receptors alpha and beta, with predominantly anti-estrogenic activity in human cell studies. Whether this translates to clinically relevant endocrine effects at dietary or supplement doses is uncertain.
  • Direct antiviral activity: Naringenin has shown direct inhibition of viral entry, replication, or assembly across multiple RNA viruses in vitro, including hepatitis C virus (NS5A (a viral non-structural protein essential for hepatitis C replication and assembly) interference), SARS-CoV-2 (Mpro (main protease, the principal coronavirus enzyme that processes viral polyproteins) and 3CLpro (3-chymotrypsin-like protease, the same coronavirus protease as Mpro) binding), dengue, and Zika; the mechanistic basis is not uniform across viruses but includes interference with host lipid pathways co-opted for viral replication.

Pharmacologically, naringenin is a flavanone with molecular formula C15H12O5 and molecular weight 272.25 Da. Selectivity: naringenin is a non-selective small-molecule flavonoid that engages multiple nuclear receptors, enzymes, and transporters at micromolar concentrations; few of its targets show high-affinity, selective binding. Oral bioavailability: absolute oral bioavailability of the naringenin aglycone in humans is low (estimated less than 15% in published pharmacokinetic studies) due to extensive intestinal and hepatic glucuronidation and sulfation; the glycoside naringin requires bacterial cleavage by gut microbiota to release naringenin, with substantial inter-individual variability. Half-life: plasma elimination half-life is approximately 2–3 hours after oral administration, with conjugated metabolites predominating in circulation. Metabolism: primary clearance is through Phase II conjugation (glucuronidation by UGT1A1, UGT1A8, UGT1A9, UGT1A10 (UDP-glucuronosyltransferases, enzymes that conjugate compounds with glucuronic acid for elimination); sulfation by SULT1A1 (sulfotransferase, an enzyme that conjugates compounds with sulfate)) rather than oxidative metabolism by cytochrome P450 enzymes. Tissue distribution: as a moderately lipophilic flavanone, naringenin distributes broadly across tissues — including liver, adipose, kidney, cardiac, and to a lesser extent central nervous system — though plasma and tissue concentrations remain low at typical dietary or supplemental doses.

Historical Context & Evolution

Naringenin and its glycoside naringin have been consumed in human diets for millennia as constituents of citrus fruits. Naringin was first isolated from grapefruit peel in 1857 by De Vry and named for the Sanskrit word narangi (orange). The aglycone naringenin was subsequently characterized as the bitter flavanone responsible for grapefruit’s distinctive taste, and the structural and stereochemical features of citrus flavanones were worked out across the early twentieth century.

Scientific interest in naringenin’s pharmacological actions grew sharply in the late 1980s and 1990s with the discovery of grapefruit’s drug-interaction profile. Bailey and colleagues at the University of Western Ontario reported in 1989 that grapefruit juice increased plasma concentrations of felodipine (a calcium channel blocker, a class of antihypertensive drugs that relax blood vessels by blocking calcium entry into vascular smooth muscle) several-fold, and subsequent mechanistic work identified inhibition of intestinal CYP3A4 as the principal mechanism. Initial attribution to naringin and naringenin shifted as later work established that furanocoumarins (bergamottin and 6’,7’-dihydroxybergamottin) cause the more durable, irreversible CYP3A4 inhibition responsible for the most clinically significant interactions, although flavanones contribute and are central to OATP transporter inhibition.

In parallel, beginning in the 1990s, Murray Huff and colleagues at Robarts Research Institute developed an extensive preclinical program demonstrating that naringenin reduces hepatic VLDL (very-low-density lipoprotein, the lipoprotein that carries triglycerides from the liver) secretion, atherogenesis, and obesity in animal models. Mulvihill and colleagues reported in 2010 that naringenin decreased atherosclerosis progression in LDL-receptor-null mice fed a high-fat Western diet by improving dyslipidemia and reducing hepatic steatosis, with reductions in aortic plaque exceeding 70% relative to untreated controls. These preclinical findings have driven sustained research interest, although translation to human trials has been limited by naringenin’s poor oral bioavailability and the absence of pharmaceutical-industry development of standardized formulations.

Human clinical investigation has consisted of small trials examining cardiovascular risk markers (lipids, inflammation, blood pressure) in healthy adults, individuals with metabolic syndrome, and patients with hepatitis C virus infection. Goldwasser and colleagues reported in 2011 that naringenin inhibited the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism, a finding that motivated subsequent clinical-trial work. The 2022 Yang et al. systematic review and meta-analysis identified, among other polyphenol findings, that naringenin significantly reduced NAFLD grade, triglycerides, total cholesterol, and LDL cholesterol while increasing HDL cholesterol across the limited human trial base.

Throughout this evolution, naringenin has not been adopted as a pharmaceutical agent by any major regulatory authority. It is sold as a dietary supplement in the United States and most jurisdictions, primarily marketed for cardiometabolic and antioxidant indications, with the underlying clinical evidence base substantially smaller than the preclinical literature.

Expected Benefits

Medium 🟩 🟩

Modest LDL and Total Cholesterol Reduction

Naringenin and naringin supplementation produce modest reductions in total and LDL cholesterol in humans. The Yang et al. (2022) systematic review and meta-analysis of randomized controlled trials of dietary polyphenols in NAFLD reported significant reductions in total cholesterol, LDL cholesterol, and triglycerides for naringenin, with effect sizes generally smaller than those of statin drugs; the same authors explicitly note that more dedicated naringenin RCTs are needed to confirm efficacy and safety. The mechanism — partial inhibition of HMG-CoA reductase, reduced apoB secretion, and PPARα-mediated upregulation of fatty-acid oxidation — is biologically coherent. Effects appear most consistent in individuals with dyslipidemia or metabolic syndrome rather than normolipidemic adults.

Magnitude: Approximately 5–10% reduction in total cholesterol and 7–12% reduction in LDL cholesterol versus placebo in pooled analyses, with substantial trial heterogeneity.

Reduction of Inflammatory Markers

Naringenin and naringin supplementation reduce systemic inflammatory markers in humans. Small randomized trials and the Naeini et al. (2021) systematic review identified reductions in C-reactive protein (CRP, a general marker of systemic inflammation produced by the liver) and IL-6 (interleukin-6, a pro-inflammatory cytokine) across small trials. The mechanism — NF-κB pathway suppression and MAPK pathway attenuation — is consistent with anti-inflammatory signals across cell and animal models.

Magnitude: Approximately 0.5–1.5 mg/L reduction in CRP and modest reductions in IL-6 versus placebo in meta-analytic estimates.

Insulin Sensitivity Improvements

Small randomized trials in adults with metabolic syndrome or impaired glucose tolerance show improvements in fasting glucose, insulin, and HOMA-IR (homeostatic model assessment of insulin resistance, a calculated index of insulin resistance from fasting glucose and insulin) following naringin or naringenin supplementation. The Den Hartogh & Tsiani (2019) review of antidiabetic properties of naringenin and the Naeini et al. (2021) NAFLD systematic review noted consistent preclinical signals and a smaller body of human evidence pointing in the same direction. The proposed mechanism includes AMPK activation, PPARγ-mediated improvement in adipose insulin signaling, and direct effects on hepatic gluconeogenesis.

Magnitude: Reductions in fasting insulin of approximately 10–20% and HOMA-IR reductions of 0.3–0.6 units in trials of metabolic syndrome populations; effects in healthy adults are smaller and less consistent.

Low 🟩

Blood Pressure Reduction in Hypertensive Adults

Some small trials of naringin or citrus flavonoid supplementation in adults with prehypertension or stage 1 hypertension report modest reductions in systolic and diastolic blood pressure. The proposed mechanism includes vascular endothelial NO (nitric oxide, a vasodilator produced by endothelial cells lining blood vessels) production, improved arterial stiffness, and reduced vascular inflammation. Trial sizes are small and the effect appears smaller than dedicated antihypertensive therapy.

Magnitude: Approximately 3–6 mmHg systolic and 2–4 mmHg diastolic blood pressure reduction in trials enrolling hypertensive adults; effects in normotensive individuals are minimal.

Hepatic Steatosis Reduction ⚠️ Conflicted

Animal models consistently show that naringenin reduces hepatic triglyceride accumulation and hepatic steatosis in diet-induced and genetic models of metabolic-dysfunction-associated steatotic liver disease (MASLD, formerly known as NAFLD; fatty liver not caused by alcohol). Small human trials in patients with MASLD have produced mixed results: some show reductions in liver enzymes (ALT (alanine transaminase), AST (aspartate transaminase)) and improved hepatic steatosis on imaging, while others show no significant change. Heterogeneity in dose, formulation, and trial duration accounts for inconsistent results.

Magnitude: Reductions of approximately 15–30% in hepatic fat content on magnetic resonance spectroscopy in some trials; no significant change in others. Liver enzyme improvements of approximately 5–15 U/L when present.

Antiviral Effects in Hepatitis C Virus Infection

Naringenin showed in vitro inhibition of hepatitis C virus secretion through interference with assembly and the host lipid machinery hijacked by the virus. A small open-label investigation in chronic hepatitis C virus patients reported transient reductions in viral load with high-dose naringenin, though the effect was modest and did not match the magnitude of direct-acting antiviral therapy. With the advent of highly effective direct-acting antivirals, clinical interest in naringenin for hepatitis C virus has waned, though mechanistic interest persists in other viral contexts (SARS-CoV-2, dengue, Zika).

Magnitude: In vitro half-maximal inhibition concentrations in the low-micromolar range; in the small clinical investigation, modest viral-load reductions of approximately 0.5 log10 IU/mL.

Speculative 🟨

Cognitive and Neuroprotective Effects

Naringenin shows neuroprotective effects in animal models of Alzheimer’s disease, Parkinson’s disease, and ischemic stroke through reduction of amyloid-beta accumulation, attenuation of microglial inflammation, and antioxidant effects in neurons. Brain penetration is limited, and human cognitive trials are essentially absent. Whether this translates to clinically meaningful cognitive benefit at oral supplement doses is uncertain.

Anticancer Activity

Cell and animal studies report naringenin-induced apoptosis (programmed cell death) in multiple cancer cell lines (breast, colon, lung, prostate) through cell-cycle arrest, caspase activation, and modulation of estrogen-receptor signaling in hormone-sensitive tumors. No human cancer trials have established naringenin as an anticancer agent, and the in vitro effective concentrations are typically far above achievable plasma levels at oral doses.

Bone Health Support

Animal studies suggest naringenin supports bone density in ovariectomy-induced osteoporosis models through estrogen-receptor-mediated mechanisms and reduced osteoclast (bone-resorbing cells) activity. No human bone-density trials have been conducted, and any benefit at typical supplement doses is speculative.

Skin Photoprotection

Topical naringenin formulations show photoprotective effects against ultraviolet-induced damage in animal and human skin-cell models, with proposed mechanisms including direct ultraviolet absorption, DNA-repair enhancement, and antioxidant activity. Small human topical studies suggest reduced erythema (skin reddening) following ultraviolet exposure when naringenin is applied beforehand. Clinical translation to commercial sunscreens or photoprotective products has been minimal.

Antiviral Effects Beyond Hepatitis C

In vitro and small clinical investigations have explored naringenin’s activity against SARS-CoV-2, dengue virus, Zika virus, and influenza. Mechanisms include interference with viral protease activity, host lipid pathways, and viral assembly. Whether these translate to clinically meaningful effects at achievable plasma concentrations remains untested in adequately powered trials.

Benefit-Modifying Factors

  • Baseline lipid status: Greater absolute reductions in LDL cholesterol and total cholesterol are observed in adults with dyslipidemia or metabolic syndrome; effects in normolipidemic adults are smaller and less consistent.
  • Baseline metabolic status: Adults with elevated fasting insulin, HOMA-IR, or impaired glucose tolerance show clearer insulin-sensitivity responses than metabolically healthy adults.
  • Gut microbiome composition: Conversion of naringin to active naringenin depends on bacterial β-glucosidase activity in the colon. Individual variation in gut microbiome composition produces substantial inter-individual variation in plasma naringenin exposure following naringin or naringin-rich citrus consumption.
  • Genetic polymorphisms in conjugating enzymes: Variants in UGT1A1 (the principal glucuronidation enzyme; the same gene relevant to Gilbert’s syndrome, a benign inherited condition with reduced bilirubin conjugation) and SULT1A1 affect the rate of naringenin conjugation and elimination, plausibly altering systemic exposure, though no clinically actionable pharmacogenomic data exist for naringenin.
  • Sex-based differences: No systematic sex-based differences in naringenin response have been established in published trials, though sample sizes are small. Pre-clinical work suggests possible sex-by-estrogen-receptor interaction effects given naringenin’s weak ER binding.
  • Pre-existing health conditions: Patients with metabolic syndrome, MASLD, or hyperlipidemia show clearer cardiometabolic responses than healthy adults; those on concurrent statin or fibrate therapy show smaller incremental lipid effects (likely a ceiling effect).
  • Age-related considerations: No published trials have specifically examined naringenin in adults over 75. Age-related changes in gut microbiome composition, hepatic conjugation capacity, and renal elimination plausibly affect both pharmacokinetics and response, but quantitative data are absent.
  • Co-intervention with dietary change: Naringenin’s metabolic effects appear most pronounced as an adjunct to caloric restriction or whole-diet improvement rather than as a stand-alone intervention. Trials enrolling participants without concurrent dietary guidance show smaller effect sizes.
  • Formulation: Pure naringenin aglycone, naringin (citrus extract), and citrus-bioflavonoid complexes differ substantially in plasma exposure profiles. Lipid-based, micellar, and cyclodextrin-complex formulations modestly improve oral absorption and may produce more reliable responses than non-formulated aglycone or whole citrus extracts.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Drug-Drug Interactions via CYP3A4 and OATP Inhibition

Naringenin (and its glycoside naringin) inhibits intestinal CYP3A4 and OATP transporters (OATP1A2, OATP2B1), which can substantially alter plasma concentrations of many prescription medications. The interaction profile parallels grapefruit juice, although the most durable inhibition involves the furanocoumarin constituents of grapefruit (bergamottin, 6’,7’-dihydroxybergamottin) rather than naringenin alone. Affected drugs include calcium channel blockers (felodipine, nifedipine), statins (simvastatin, lovastatin, atorvastatin), some immunosuppressants (cyclosporine, tacrolimus), some benzodiazepines (midazolam, triazolam), the antiarrhythmic amiodarone, certain anticancer agents, and others. Concentrations of affected drugs can increase by two- to fivefold or more in some cases, with consequences ranging from mild side-effect amplification to clinically significant toxicity (rhabdomyolysis (muscle breakdown that releases damaging contents into the bloodstream) with high-dose statins; hypotension with calcium channel blockers; over-immunosuppression with cyclosporine).

Magnitude: Variable; up to several-fold increases in plasma exposure for the most-affected drugs; the effect can persist for 24–72 hours after a single high-naringenin dose due to enzyme turnover requirements.

Medium 🟥 🟥

Gastrointestinal Effects

Mild gastrointestinal effects including nausea, abdominal discomfort, diarrhea, and increased flatulence have been reported in clinical trials of naringenin and naringin supplements at higher doses. These are typical of botanical extract intolerance and rarely cause discontinuation. Citrus fruit consumption at typical dietary intakes is generally well tolerated even in individuals reporting symptoms with concentrated supplements.

Magnitude: Reported in approximately 5–15% of participants in higher-dose supplement trials; rare at dietary intake levels.

Estrogenic and Anti-Estrogenic Endocrine Effects

Naringenin shows weak binding to estrogen receptors alpha and beta, with predominantly anti-estrogenic activity in cell models. Whether this produces clinically meaningful endocrine effects at oral supplement doses is unestablished; the concern is most relevant for patients with hormone-sensitive cancers (breast, endometrial), pregnancy, and concurrent hormone therapy. No clinical adverse events attributable to naringenin’s endocrine effects have been documented in published trials, but caution is reasonable in these populations.

Magnitude: Not quantified in available studies.

Low 🟥

Photosensitivity

The furanocoumarins of grapefruit (and, to a lesser extent, certain other citrus) can produce photosensitivity reactions. Pure naringenin lacks furanocoumarin structure and has not been associated with phototoxic reactions; the concern is therefore limited to whole-citrus extracts that may contain residual furanocoumarins.

Magnitude: Not quantified in available studies; the risk is essentially absent for purified naringenin.

Risk in Hyperbilirubinemia

Because naringenin is conjugated by UGT1A1 (the same enzyme deficient in Gilbert’s syndrome and Crigler-Najjar syndrome, a rarer and more severe inherited bilirubin-conjugation disorder), individuals with severe UGT1A1 deficiency could theoretically experience elevated naringenin exposure or modest competition with bilirubin conjugation. No clinical adverse events have been documented; the concern is theoretical.

Magnitude: Not quantified in available studies.

Speculative 🟨

Long-Term Safety in Healthy Adults

Almost all human safety data for naringenin and naringin supplements come from trials of 12 weeks or shorter, mostly in dyslipidemic, metabolic syndrome, or MASLD populations. The safety profile of multi-year supplementation in metabolically healthy adults seeking longevity benefits is uncharacterized. Long-term effects on hepatic conjugation enzymes, gut microbiome composition, or other downstream systems have not been studied.

Pregnancy and Lactation

Naringenin is generally avoided in pregnancy and lactation due to lack of safety data and theoretical concerns from estrogen-receptor binding. There are no controlled human reproductive studies, so this is conservative rather than evidence-based.

Impact on Thyroid Function

Some flavonoids inhibit thyroid peroxidase (the enzyme responsible for thyroid hormone synthesis) at high concentrations in vitro. Whether naringenin at supplement doses produces clinically meaningful thyroid effects is unstudied; the concern is theoretical and likely irrelevant at dietary intake levels.

Effects on Reproductive Hormones

In animal studies, high-dose naringenin has produced modest changes in serum testosterone, estradiol, and gonadotropin concentrations. Whether this translates to humans at supplement doses is unknown; controlled human reproductive-hormone trials are absent.

Risk-Modifying Factors

  • Concurrent medication use: This is the dominant risk-modifying factor. Patients on statins, calcium channel blockers, immunosuppressants, certain benzodiazepines, antiarrhythmics, or anticancer drugs metabolized by CYP3A4 face significantly amplified plasma drug exposure when naringenin or naringin-rich citrus extracts are used. Reference databases (Memorial Sloan Kettering, drugs.com, FDA) broadly flag grapefruit and grapefruit-derived flavonoids as one of the more clinically important food-drug interaction categories.
  • Pre-existing hepatic impairment: Patients with significant hepatic dysfunction face altered conjugation capacity and reduced clearance of both naringenin and concurrent drugs whose metabolism naringenin alters; the combination raises the risk of unexpected drug exposure.
  • Baseline biomarker levels: Elevated baseline ALT, AST, GGT (gamma-glutamyl transferase, a liver enzyme that rises with hepatobiliary stress), or bilirubin levels indicate altered hepatic processing capacity that may amplify naringenin’s interaction profile or signal underlying conditions (e.g., Gilbert’s syndrome) where naringenin’s UGT1A1 conjugation pathway is partially impaired. Likewise, elevated baseline serum creatinine or reduced eGFR (estimated glomerular filtration rate, a calculated measure of kidney function) identifies individuals with reduced renal clearance, plausibly increasing systemic exposure and adverse-event risk; concurrent prescription drug levels are similarly affected.
  • UGT1A1 polymorphisms (Gilbert’s syndrome): Approximately 5–10% of the population has reduced UGT1A1 activity (Gilbert’s syndrome). The clinical consequence for naringenin disposition is theoretical but warrants awareness.
  • Pre-existing hormone-sensitive conditions: In patients with breast cancer, endometrial cancer, endometriosis, or those on hormone-replacement therapy or hormonal contraception, naringenin’s weak estrogen-receptor activity is a relevant factor, even though no clinical adverse signal has been documented.
  • Pre-existing reproductive concerns: Pregnancy, lactation, and active fertility treatment are contexts in which the absence of safety data argues for conservative avoidance of concentrated naringenin supplements (whole-fruit citrus consumption is not implicated).
  • Age-related considerations: Older adults are more likely to be on multiple CYP3A4-metabolized medications, raising the practical risk of significant interactions; slower titration and review of medication lists are appropriate.
  • Polypharmacy: The greater the number of concurrent medications metabolized by CYP3A4 or transported by OATPs, the greater the cumulative risk of clinically meaningful drug interactions.
  • Sex-based differences: No clinically relevant sex-based differences in adverse-event profile have been established in published trials.
  • Genetic polymorphisms: Variation in UGT1A enzymes, SULT1A1, and CYP3A4 itself plausibly affects both naringenin disposition and the magnitude of drug-interaction effects, but no clinically actionable pharmacogenomic test guides naringenin use.
  • Product quality and formulation: Whole citrus extracts contain furanocoumarins absent from purified naringenin; products labeled as “citrus bioflavonoid complex” may produce greater drug-interaction effects than purified naringenin aglycone. Standardization disclosure is variable across commercial products.

Key Interactions & Contraindications

  • CYP3A4 substrates with narrow therapeutic index (e.g., cyclosporine, tacrolimus, sirolimus, everolimus): Caution. Substantial increases in plasma exposure can produce over-immunosuppression. Mitigating action: avoid combination; if combination is unavoidable, monitor immunosuppressant trough levels closely under physician supervision.
  • Statins (e.g., simvastatin, lovastatin, atorvastatin): Caution. Increased plasma concentrations raise the risk of muscle toxicity (myopathy) and rhabdomyolysis. Mitigating action: avoid combination with simvastatin and lovastatin (most strongly affected); pravastatin and rosuvastatin show minimal interaction and can substitute.
  • Calcium channel blockers (e.g., felodipine, nifedipine, amlodipine, nisoldipine): Caution. Increased plasma concentrations can produce excessive vasodilation, hypotension, and reflex tachycardia. Mitigating action: avoid combination with felodipine and nisoldipine (most strongly affected); separate dosing and monitor blood pressure if combination cannot be avoided.
  • Antiarrhythmics (e.g., amiodarone, dronedarone, quinidine): Caution. Amiodarone exposure can increase severalfold with potential for QT prolongation (a heart-rhythm abnormality) and pro-arrhythmia. Mitigating action: avoid combination.
  • Benzodiazepines (e.g., midazolam, triazolam, alprazolam): Caution. Increased exposure produces excessive sedation. Mitigating action: avoid combination, especially with midazolam and triazolam; lorazepam, oxazepam, and temazepam are minimally affected.
  • Anticoagulants (e.g., warfarin, rivaroxaban, apixaban): Monitor. Warfarin metabolism is partly affected by CYP3A4; case reports describe increased INR (international normalized ratio, a measure of how long blood takes to clot) with grapefruit consumption. Mitigating action: monitor INR more frequently if naringenin or citrus flavonoid supplement is initiated alongside warfarin.
  • Anticancer drugs (e.g., dasatinib, nilotinib, imatinib, cyclophosphamide, tamoxifen): Caution. Many tyrosine kinase inhibitors and chemotherapy agents are CYP3A4 substrates with narrow therapeutic windows. Mitigating action: avoid combination; consult oncology team before initiation.
  • Phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil): Caution. Increased exposure can amplify hypotensive effects. Mitigating action: avoid combination; separate dosing and monitor blood pressure if combination is unavoidable.
  • Erectile dysfunction and pulmonary hypertension drugs (sildenafil, tadalafil for pulmonary arterial hypertension): Caution. Same CYP3A4-mediated mechanism with potentially serious hemodynamic consequences.
  • Hormone therapy (oral estrogens, hormonal contraceptives): Monitor. Theoretical interaction through estrogen-receptor binding and CYP3A4-mediated metabolism of synthetic estrogens. Mitigating action: monitor for breakthrough symptoms or unexpected hormonal effects; consider non-naringenin alternatives in patients on hormonal contraception.
  • Other CYP3A4-metabolized drugs (e.g., buspirone, carbamazepine, certain antifungals, certain HIV protease inhibitors): Monitor. Effects vary by individual drug; consult prescribing information.
  • OTC analgesics metabolized by CYP3A4 (e.g., dextromethorphan-containing cold formulations, certain OTC pain combinations): Monitor. Increased exposure can amplify central nervous system effects; mitigating action is to separate timing or choose alternative agents.
  • OTC sedating antihistamines and motion-sickness drugs (e.g., diphenhydramine, dimenhydrinate, chlorpheniramine): Monitor. CYP3A4-mediated metabolism can be altered, raising plasma levels and amplifying sedation; mitigating action is to separate timing and use the lowest effective dose.
  • OTC proton pump inhibitors (e.g., omeprazole, esomeprazole): Monitor. PPI metabolism via CYP-mediated pathways may be modestly affected; the clinical significance is small but worth noting in heavy users.
  • Other CYP3A4-inhibiting supplements (e.g., goldenseal, black pepper extract / piperine, kava, milk thistle): Additive. Combining multiple CYP3A4-inhibiting supplements compounds the interaction risk; mitigating action is to separate use or avoid stacking.
  • St. John’s Wort (CYP3A4 inducer): Caution. St. John’s Wort opposes naringenin’s CYP3A4 inhibition; combination produces unpredictable net effects on prescription drug levels.
  • Other citrus flavonoids and grapefruit products (e.g., hesperidin, diosmin, bergamot, grapefruit-seed extract): Additive. Combining naringenin supplements with grapefruit juice, whole-grapefruit consumption, or other citrus-flavonoid extracts multiplies the CYP3A4 inhibition.
  • Other lipid-lowering supplements (e.g., red yeast rice, berberine, niacin, plant sterols): Additive on lipid endpoints. Combinations may produce greater LDL reduction but also greater interaction risk for CYP3A4 substrates; mitigating action is to monitor lipid panel and adjust statin dosing under physician supervision when applicable.
  • Hypotensive supplements (e.g., hibiscus, garlic extract, fish oil at high dose): Additive on blood pressure. Combinations could produce excessive blood-pressure reduction in hypertensive adults; mitigating action is to monitor blood pressure during initiation.
  • Hypoglycemic supplements (e.g., berberine, alpha-lipoic acid, gymnema): Additive on glucose lowering. Combinations could increase hypoglycemia risk in adults already on glucose-lowering agents; mitigating action is to monitor fasting glucose and HbA1c (glycated hemoglobin, a measure of average blood glucose over the prior 2–3 months).

Populations who should avoid this intervention:

  • Patients on solid-organ transplant immunosuppression at any time post-transplant (cyclosporine, tacrolimus, sirolimus, everolimus)
  • Patients on simvastatin (any dose), lovastatin (any dose), or amiodarone (any dose)
  • Patients on narrow-therapeutic-index CYP3A4 substrates (cancer chemotherapy, certain antiarrhythmics) within 7 days of new prescription initiation
  • Patients with active hormone-sensitive cancer (breast or endometrial cancer at any stage, including stage 0/in situ) without specialist oversight
  • Patients with severe hepatic impairment (Child-Pugh Class B or C)
  • Patients with severe renal impairment (eGFR less than 30 mL/min/1.73m²)
  • Pregnancy (any trimester) and lactation (safety not established)
  • Children and adolescents under 18 (insufficient pediatric supplement safety data; dietary citrus consumption is not implicated)
  • Recent surgery or planned major surgery within 7 days (intestinal CYP3A4 expression has not yet returned toward baseline)
  • Documented citrus allergy or hypersensitivity to citrus flavonoids

Risk Mitigation Strategies

  • Comprehensive medication review before initiation: The dominant safety concern with naringenin is drug-drug interaction via CYP3A4 inhibition. A pre-initiation comparison of the current medication list against published lists of CYP3A4 substrates (Indiana University’s Drug Interaction Database, FDA labeling) is the single step described in reference sources as preventing most clinically meaningful interaction risk.
  • Use of purified naringenin aglycone rather than whole-citrus extracts where available: Whole grapefruit extracts contain furanocoumarins (bergamottin, 6’,7’-dihydroxybergamottin) responsible for the most durable, irreversible CYP3A4 inhibition. Purified naringenin lacks furanocoumarin structure and produces a milder, more reversible inhibition profile, reducing but not eliminating interaction risk.
  • Concurrent grapefruit consumption: Combining naringenin supplements with grapefruit juice or whole grapefruit multiplies CYP3A4 inhibition; reference sources describe avoidance of daily grapefruit consumption while supplementing.
  • Low starting dose: Reference protocols begin with 50–100 mg of naringenin once daily for 7–14 days, advancing to twice daily if tolerated and no medication-interaction concerns are noted. This staged approach is described as a way to detect gastrointestinal side effects and any interaction-related changes in concurrent drug effects.
  • Separation of supplement timing from CYP3A4-metabolized medications where unavoidable: Although intestinal CYP3A4 inhibition can persist for hours, separating naringenin supplement timing by at least 4 hours from doses of CYP3A4-metabolized medications partially reduces the interaction magnitude.
  • Discontinuation 7 days before any planned anesthesia, narrow-therapeutic-index drug initiation, or major surgery: Allows intestinal CYP3A4 expression to return toward baseline.
  • Avoidance in pregnancy, lactation, and during active fertility treatment: Reflects the absence of safety data and theoretical estrogen-receptor concerns.
  • Reassessment at 8–12 weeks if used for cardiometabolic indications: Lipid, glucose, and inflammatory markers that have not improved by 12 weeks at validated supplement doses are unlikely to improve with longer dosing alone; continued supplementation without measurable benefit unfavorably tilts the risk-benefit balance given the persistent interaction risk.
  • Taking with food: Improves absorption of the lipophilic flavanone and reduces gastrointestinal side effects.

Therapeutic Protocol

Standard protocols for oral naringenin or naringin supplementation are drawn from the small set of completed human trials and consumer-reference summaries on Memorial Sloan Kettering’s herbs database, drugs.com, and academic reviews. There is no FDA-approved oral naringenin product; protocols below describe supplement use for cardiometabolic markers, MASLD, and antioxidant indications, not approved medical therapy. Two principal therapeutic approaches coexist in cardiometabolic dyslipidemia management: a pharmaceutical approach using statins and other lipid-lowering drugs, codified across cardiology society guidelines (e.g., American College of Cardiology / American Heart Association cholesterol guidelines — bodies whose member cardiologists derive direct revenue from prescribing the drugs they endorse, and which receive substantial pharmaceutical industry funding; with cardiology-clinic protocols at academic centers including Cleveland Clinic, Mayo Clinic, and Brigham and Women’s Hospital), with a substantially larger evidence base and broader regulatory approval; and a supplement-based or whole-food approach incorporating citrus flavonoids, popularized through integrative- and functional-medicine practitioners (e.g., Andrew Weil at the University of Arizona Center for Integrative Medicine, and the integrative-medicine programs at Memorial Sloan Kettering and the Cleveland Clinic Center for Functional Medicine — programs whose practitioners and affiliated providers may sell or recommend supplement products from which they derive direct or indirect revenue), with a smaller evidence base focused on modest incremental cardiometabolic improvements. Institutional payers (insurers, national health systems) carry a structural incentive favoring lower-cost generic statins over branded supplements, which can shape guideline formation, research-funding priorities, and which interventions are reimbursed; this constitutes a potential source of bias on both sides of the debate. Each approach is presented here as evidence-supported, with neither framed as the default.

  • Standard oral dose for cardiometabolic and inflammatory markers: 100–500 mg of naringenin (or equivalent citrus flavanone extract standardized to naringin and naringenin content) once or twice daily. Higher doses (up to 1500 mg/day in research-grade investigations) have been used in hepatitis C virus and hepatic-steatosis trials but carry greater drug-interaction risk.
  • Starting dose: 50–100 mg of naringenin once daily with food for 7–14 days, then advance to twice daily if tolerated and no medication-interaction concerns are present.
  • Typical duration of use: 8–12 weeks per cycle, matching most validated trial durations. Continuous multi-year supplementation is not supported by published safety data.
  • Best time of day: Naringenin has no inherent circadian optimum at supplement doses. Twice-daily dosing is typically taken with breakfast and dinner to maintain steadier plasma concentrations given the short elimination half-life.
  • Half-life: Plasma elimination half-life is approximately 2–3 hours for the conjugated metabolites that predominate after oral dosing. Pure aglycone has very low oral bioavailability; lipid-based, micellar, and cyclodextrin-complex formulations modestly improve absorption.
  • Single vs. split dosing: Twice-daily split dosing (morning and evening with meals) better matches the short half-life and produces more sustained plasma exposure than once-daily dosing.
  • Genetic considerations: No clinically actionable pharmacogenomic data exist for naringenin. Variation in UGT1A1 (Gilbert’s syndrome and other variants), SULT1A1, and CYP3A4 itself could plausibly affect both naringenin disposition and interaction profile; broader pharmacogenetically relevant variants such as APOE4 (a lipid-handling gene variant linked to cardiovascular and cognitive outcomes), MTHFR (a folate-metabolism enzyme variant), and COMT (a neurotransmitter-degrading enzyme variant influencing dopamine clearance) have not been studied in relation to naringenin response. No test currently guides naringenin dosing in practice.
  • Sex-based considerations: No systematic sex-based differences in naringenin response have been established in published trials. Pre-clinical work suggests possible sex-by-estrogen-receptor interaction effects given naringenin’s weak ER binding, but no sex-specific dosing differences are used in practice.
  • Age-related considerations: Older adults — especially above age 75 — face higher risk of clinically meaningful CYP3A4 drug interactions because of more frequent polypharmacy with CYP3A4-metabolized medications, and have not been specifically studied at standard supplement doses for cardiometabolic outcomes. Reference sources describe slower titration and closer medication review in this older subgroup.
  • Baseline biomarkers: Higher baseline LDL cholesterol, total cholesterol, fasting insulin, HOMA-IR, and CRP identify individuals more likely to see measurable cardiometabolic responses; well-controlled baseline values predict smaller effect sizes.
  • Pre-existing conditions: Adults with metabolic syndrome, MASLD, or moderate dyslipidemia not currently on statin therapy are the populations with the most evidence-supported potential benefit. Adults already optimally managed on statins or fibrates have a smaller evidence base for incremental measurable effect.

Discontinuation & Cycling

  • Duration of use: Supplement protocols are typically described in 8–12-week cycles, mirroring most validated trial durations. Continuous multi-year supplementation is not supported by available human safety data, and continuous CYP3A4 inhibition adds chronic interaction risk.
  • Withdrawal effects: No withdrawal syndrome, rebound dyslipidemia, or rebound inflammatory marker elevation has been reported on discontinuation of oral naringenin or naringin supplements. Cardiometabolic improvements that occurred on supplementation are likely to regress on discontinuation if underlying lifestyle inputs are not maintained.
  • Tapering: Tapering is not required. Naringenin can be stopped abruptly without physiological consequence at typical supplement doses.
  • Cycling: No controlled trial has compared continuous to cycled naringenin use. A pragmatic 8-to-12-week-on, several-week-off cycle is reasonable in the absence of long-term safety data and reduces cumulative drug-interaction exposure.
  • Discontinuation thresholds: Reference protocols describe discontinuation if any new medication is initiated that is metabolized by CYP3A4 with a narrow therapeutic index, if unexpected effects of concurrent medications develop, if persistent gastrointestinal symptoms occur, or if no measurable benefit is seen after a full 12-week cycle when used for cardiometabolic indications.
  • Pre-procedural discontinuation: A 7-day discontinuation window before any planned surgery, anesthesia, or initiation of a new narrow-therapeutic-index medication is described as allowing intestinal CYP3A4 expression to return toward baseline.

Sourcing and Quality

  • Standardization disclosure: Reputable products explicitly disclose the form (purified naringenin aglycone, naringin, or citrus bioflavonoid extract), the per-capsule milligrams of active naringenin, and whether the product is standardized to a specific aglycone-to-glycoside ratio. Products listing only “citrus bioflavonoid complex” without quantification are described in reference sources as providing insufficient information for evaluation.
  • Pure aglycone vs. citrus extract: Purified naringenin aglycone produces a milder, more reversible CYP3A4 inhibition profile than whole-grapefruit extracts (which contain furanocoumarins responsible for the most durable inhibition). For supplement use, purified naringenin or naringin is generally preferable to grapefruit-derived extracts.
  • Independent third-party testing: ConsumerLab does not maintain a dedicated naringenin product-testing category. Selecting a product from a brand that publishes Certificates of Analysis from an independent laboratory or that holds NSF, USP, or Informed Sport certification mitigates label-claim variability.
  • Reputable brands and standardized extracts: Several supplement brands (Life Extension, Pure Encapsulations, Swanson, NOW Foods, Jarrow Formulas) market standalone naringenin or naringin products with disclosed standardization and Certificates of Analysis. Citrus flavonoid blends (often combining naringenin with hesperidin, diosmin, and rutin) are also widely sold.
  • Multi-ingredient stimulant blends: Many naringenin- or grapefruit-extract-containing products are sold inside multi-ingredient stimulant blends (caffeine, synephrine, green tea extract). These add cardiovascular and interaction risk and obscure attribution of any observed effect; standalone standardized naringenin is preferable for evaluation.
  • Storage and stability: Naringenin is moderately heat- and light-sensitive. Standardized extracts should be stored at room temperature in a dry, opaque container away from heat and direct sunlight.
  • Cost and accessibility: A 60-capsule bottle of 250 mg naringenin (or equivalent citrus flavanone extract) typically costs USD 15–40 in the United States, with substantial price variation across brands and formulations. Standalone naringenin products are less widely stocked in retail supplement stores than multi-ingredient citrus flavonoid complexes.

Practical Considerations

  • Time to effect: Cardiometabolic markers (lipids, fasting insulin, CRP) in published trials typically show measurable changes within 4–8 weeks of consistent dosing, with maximal effects emerging by 12 weeks. Hepatic steatosis improvements typically require 12 weeks or longer. Effects on drug metabolism (CYP3A4 inhibition) appear within hours to days of initiation.
  • Common pitfalls: Failing to review concurrent medications for CYP3A4 interactions; combining naringenin with grapefruit consumption; using non-standardized products with unknown active content; expecting lipid-lowering effects in normolipidemic adults; treating naringenin as a substitute for statins or other established cardiometabolic therapies rather than as an adjunct or option in adults not yet on pharmaceutical therapy; ignoring the brief but clinically meaningful CYP3A4-inhibition window when planning surgeries or new prescriptions.
  • Regulatory status: Oral naringenin and naringin extracts are regulated as dietary supplements in the United States and most jurisdictions; they are not FDA-approved for the treatment of any condition. The FDA has issued consumer guidance about grapefruit-drug interactions because of the same flavanone-and-furanocoumarin chemistry.
  • Cost and accessibility: Standalone naringenin and citrus flavanone supplements are relatively affordable and widely available online; dietary intake from grapefruit, oranges, tomatoes, and other citrus or related fruits is even more accessible and produces measurable plasma exposure at typical consumption levels.

Interaction with Foundational Habits

  • Sleep: No direct effect of oral naringenin on sleep architecture has been documented in controlled human trials. Naringenin lacks the stimulant cAMP-elevating profile of caffeine and theophylline. Anecdotal reports of sleep disruption with high-dose citrus flavonoid supplements likely reflect added stimulant ingredients in combination products rather than naringenin itself.
  • Nutrition: Naringenin’s most consistent metabolic effects in human trials emerge alongside caloric restriction or whole-diet improvement (e.g., Mediterranean dietary patterns rich in citrus and other polyphenol sources). Taking the supplement dose with a meal containing some dietary fat improves absorption of the lipophilic flavanone. Whole-fruit citrus consumption (oranges, grapefruit if no medication concerns, tomatoes) provides naringenin alongside synergistic flavonoids and fiber and is preferable to isolated supplementation for individuals without specific cardiometabolic indications.
  • Exercise: Naringenin’s AMPK-activating and lipid-oxidation-supporting effects could theoretically complement exercise-induced metabolic improvements, but no controlled trial has shown that pre-exercise naringenin produces incremental fat loss or performance improvements beyond exercise alone. Naringenin has not been studied as an ergogenic aid.
  • Stress management: No direct effect of oral naringenin on cortisol, the hypothalamic-pituitary-adrenal axis, or perceived stress has been documented in human trials. In vitro and animal studies suggest naringenin may modestly attenuate stress-induced inflammatory responses through NF-κB pathway suppression, but the systemic clinical implications at supplement doses are uncertain.

Monitoring Protocol & Defining Success

Baseline laboratory and clinical assessment is described in reference protocols as the first step before initiating oral naringenin supplementation, particularly in adults on multiple prescription medications or those using naringenin for specific cardiometabolic indications. The cadence below reflects the limited published-trial monitoring schedules and conservative practice based on the mechanistic risk profile.

Ongoing monitoring: medication review at initiation and at any new prescription change; lipid panel and metabolic markers at 8–12 weeks if used for cardiometabolic indications; liver enzymes at baseline and 12 weeks for those with MASLD or hepatic conditions; periodic reassessment of supplement value if benefits are not measurable.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Total cholesterol 150–200 mg/dL Lipid response 12-hour fast; conventional reference less than 200 mg/dL
LDL cholesterol Less than 100 mg/dL Primary lipid endpoint 12-hour fast; lower targets for those with cardiovascular disease history; conventional reference less than 130 mg/dL
HDL cholesterol Greater than 60 mg/dL Cardiometabolic tracking Higher is better; small HDL effects observed in some citrus flavonoid trials
Triglycerides Less than 100 mg/dL Cardiometabolic tracking 12-hour fast required; conventional reference less than 150 mg/dL
Fasting glucose 72–85 mg/dL Baseline metabolic status 8–12 hour fast; conventional reference less than 100 mg/dL
Fasting insulin 2–5 µIU/mL Insulin sensitivity tracking Fasting; conventional upper limit ~25 µIU/mL; lower values indicate better insulin sensitivity
HOMA-IR Less than 1.0 Calculated insulin-resistance index Homeostatic model assessment of insulin resistance, derived from fasting glucose and insulin; conventional concern above 2.5
HbA1c 4.8–5.2% Average glucose exposure over 2–3 months Glycated hemoglobin; fasting not required; conventional reference less than 5.7%
hs-CRP Less than 1.0 mg/L Inflammatory marker High-sensitivity C-reactive protein; conventional cardiovascular risk thresholds: less than 1.0 (low), 1.0–3.0 (average), greater than 3.0 (high)
ALT Less than 25 U/L (men), less than 22 U/L (women) Hepatic safety baseline Alanine transaminase; conventional upper limit 40–56 U/L; baseline plus repeat at 12 weeks
AST Less than 25 U/L Hepatic safety baseline Aspartate transaminase; conventional upper limit 40 U/L
GGT Less than 25 U/L Hepatic and oxidative-stress marker Gamma-glutamyl transferase; useful adjunct to ALT/AST in assessing hepatic status
INR (if on warfarin) Within target range Bleeding-risk monitoring International normalized ratio; recheck within 2 weeks of naringenin initiation in warfarin-treated patients

Qualitative markers to track:

  • New or unusual effects of concurrent prescription medications during naringenin use
  • Gastrointestinal tolerance during titration (nausea, diarrhea, abdominal discomfort)
  • Energy stability and any subjective metabolic changes
  • Body-composition trend over months in those using naringenin alongside dietary change
  • Subjective sense of inflammation-related symptoms (joint stiffness, fatigue) over months
  • Adherence to scheduled medication review at initiation and prescription changes

Emerging Research

Several research directions could materially refine the understanding of naringenin over the next several years. Both supportive and potentially unfavorable directions are represented.

  • Bone fracture supplementation trial: Naringenin Supplementation in Bone Fracture Patients (NCT06612762, recruiting; 70 participants; daily oral naringenin versus placebo) could clarify whether naringenin’s preclinical bone-supportive signals translate to measurable clinical benefit in fracture healing.
  • Bioavailability and energy expenditure trial: Effect of Naringenin and Beta Carotene on Energy Expenditure (NCT04697355, completed; single-subject case study, n=1, assessing energy expenditure and glucose metabolism following oral naringenin and beta-carotene) and the earlier Safety and Pharmacokinetics of an Extract of Naringenin (NCT03582553, completed; 18 participants) anchor the human pharmacokinetic and safety dataset on which larger trials may build.
  • Cardiovascular endpoints in dyslipidemia: Continued small randomized trials of naringenin and naringin in adults with mild-to-moderate dyslipidemia, building on the Yang et al. 2022 meta-analysis and the Adams et al. 2025 systematic review, are likely to refine the magnitude of effect and identify subpopulations most likely to benefit.
  • Improved oral formulations: Naringenin-loaded solid lipid nanoparticles (Ji et al., 2016) is one of several formulation studies showing that solid lipid nanoparticles, micelles, and cyclodextrin complexes can substantially increase oral naringenin bioavailability over conventional aglycone supplementation; if reproducible in humans, smaller doses with potentially better risk-benefit profiles may emerge.
  • SARS-CoV-2 antiviral exploration: Naringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro (Clementi et al., 2021) reports in vitro inhibition of SARS-CoV-2 infection; whether this translates to clinically meaningful antiviral effect in humans is unestablished but motivates additional investigation in viral infection contexts.
  • Tyrosine kinase inhibitor interactions: Hesperetin and Naringenin sensitize HER2 positive cancer cells to death (Chandrika et al., 2016; HER2 = human epidermal growth factor receptor 2, a cell-surface receptor overexpressed in some breast and gastric cancers) and Effect of grapefruit juice on the pharmacokinetics of nilotinib (Yin et al., 2010) continue to refine the understanding of when naringenin and grapefruit-derived flavonoids meaningfully alter exposure to or activity of anticancer drugs, with implications for both interaction risk and potential dose-sparing strategies.
  • Cognitive Decline and citrus flavonoid trial: Clinical and Biological Effects of Citrus-phytochemicals in Subjective Cognitive Decline (NCT04744922, completed; 80 participants on standardized citrus-peel extract containing auraptene and naringenin) addresses whether citrus flavonoids influence cognitive function; full results would help bound naringenin’s neurocognitive translation to humans.
  • Microbiome interactions: Increasing recognition that gut microbiome composition determines naringenin (and broader flavonoid) bioavailability is driving research into microbiome-stratified responder analyses; Beneficial effects of citrus flavanones naringin and naringenin on lipid metabolism (Yang et al., 2022) summarizes the host-microbiome axis relevant to naringenin pharmacokinetics.
  • Long-term safety: No long-term (multi-year) safety data exist for naringenin supplementation. Whether continuous daily supplementation produces sustained CYP3A4 inhibition with cumulative drug-interaction risk, gut microbiome changes, or other downstream effects is an unanswered safety question that adequately powered long-term trials would help resolve.
  • Estrogen-receptor and hormone-sensitive cancer interactions: Whether naringenin’s weak estrogen-receptor activity translates to clinically meaningful effects (favorable or unfavorable) in patients with breast or endometrial cancer remains unestablished; targeted research in these populations would clarify whether existing precautionary guidance is necessary or excessive.

Conclusion

Naringenin sits at the intersection of dietary phytochemistry, drug-interaction pharmacology, and supplement marketing. Its distinctive feature is the dual identity of being both a normal constituent of citrus diets and a potent modulator of liver and gut enzymes that determine how the body processes many prescription medications.

The most consistent human evidence is for modest reductions in total and “bad” cholesterol and in inflammatory markers, supported by a small meta-analysis. Insulin sensitivity may improve modestly in adults with metabolic syndrome, with smaller signals for blood-pressure reduction in hypertensive adults and for hepatic-fat reduction in fatty liver disease. Animal studies show striking effects on atherosclerosis and obesity that have not fully translated to humans, in part because of poor oral bioavailability. Anticancer, neuroprotective, and antiviral applications remain confined to preclinical and small clinical investigations.

The dominant safety concern is interaction with prescription medications metabolized by intestinal liver-enzyme systems shared with grapefruit, which can substantially raise plasma drug concentrations of statins, calcium channel blockers, immunosuppressants, and certain anticancer agents. Direct toxicity of the molecule itself appears low at supplement and dietary doses. Long-term safety in healthy adults seeking longevity benefits is uncharacterized and the small trial base limits the strength of any cardiometabolic claim. The evidence base reflects competing financial interests on both sides: pharmaceutical-funded trials and cardiology professional bodies on one side, and supplement vendors and integrative-medicine practices on the other; institutional payers favor lower-cost generics, a further source of structural bias.

Top - Benefits - Risks - Protocol